About: Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy
Creator	Willan, John Booth, Stephen Collins, Graham Neelakantan, Pratap Browning, Joe Chen, Lucia Dhillon, Elissa Dungarwalla, Moez Dutton, David Eyre, Toby Farnell, Rachel Gray, Nicola Griffith, John Hunter, Alicia Katz, Harley Khan, Dalia Mohamed, Yasmin Peniket, Andy Polzella, Paolo Prideaux, Steven Sternberg, Alex Wong, Henna
source	Medline; PMC
abstract	OBJECTIVES: We sought to characterise the outcomes of patients with haematological malignancy and SARS‐CoV‐2 infection in hospital in our regional network of 7 hospitals. METHODS: Consecutive hospitalised patients with haematological malignancy and SARS‐CoV‐2 infection were identified from 01/03/2020 to 06/05/2020. Outcomes were categorised as death, resolved, or ongoing. The primary outcome was preliminary case fatality rate (pCFR), defined as the number of cases resulting in death as a proportion of all diagnosed cases. Analysis was primarily descriptive. RESULTS: 66 Patients were included, overall pCFR was 51.5%. Patients ≥ 70 years accounted for the majority of hospitalised cases (42, 63%) and fatalities (25, 74%). Mortality was similar between females (52%) and males (51%). Immunosuppressive or cytotoxic treatment within 3 months of the diagnosis of SARS‐CoV‐2 infection was associated with a significantly higher preliminary Case Fatality Rate (pCFR) of 70%, compared with 28% in those not on active treatment (P = 0.0013, 2 proportions z‐test). CONCLUSIONS: Mortality rates in patients with haematological malignancy and SARS‐CoV‐2 infection in hospital are high supporting measures to minimise the risk of infection in this population.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1111/ejh.13469
bibo:pmid	32544294
has license	no-cc
sha1sum (hex)	14a10207629825f528885f6872c7b2aab2360f81
schema:url	https://doi.org/10.1111/ejh.13469
resource representing a document's title	Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy
has PubMed Central identifier	PMC7323336
has PubMed identifier	32544294
schema:publication	Eur J Haematol
resource representing a document's body	covid:14a10207629825f528885f6872c7b2aab2360f81#body_text
is schema:about of	named entity 'WORD' named entity 'infection' named entity 'haematological malignancy' named entity 'haematology' named entity 'Coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'purine analogues' named entity 'risk factor' named entity 'SARS-CoV-2' named entity 'haematological malignancy' named entity 'retrospective cohort studies' named entity 'reverse transcriptase' named entity 'chemotherapy' named entity 'heterogeneity' named entity 'immunosuppressive' named entity 'curative intent' named entity 'disease control' named entity 'multivariate analysis' named entity 'haematological malignancy' named entity 'cohort study' named entity 'virus' named entity 'case fatality rate' named entity 'haematological' named entity 'haematological malignancy' named entity 'clinical trials' named entity 'haematological malignancy' named entity 'England' named entity 'small numbers' named entity 'chemotherapy' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'COVID' named entity 'clinical trials' named entity 'COVID' named entity 'haematological malignancy' named entity 'follicular lymphoma' named entity 'solid organ' named entity 'SARS-CoV-2' named entity 'leukaemia' named entity 'malignant' named entity 'haematological cancers' named entity 'respiratory infections' named entity 'intensive care' named entity 'mortality rate' named entity 'haematological malignancies' named entity 'COVID' named entity 'haematological cancers' named entity 'COVID' named entity 'COVID-19' named entity 'COVID-19' named entity 'vaccine' named entity 'polycythaemia vera' named entity 'infection' named entity 'pre-print' named entity 'RNA' named entity 'COVID' named entity 'haematological malignancy' named entity 'haematological cancers' named entity 'myeloma' named entity '06/05' named entity 'haematological malignancy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software